GlassScriptPhysician profile
Kristopher Stewart Oldham
NPI 1619357787
$4,556.01
in general payments reported to CMS, 2019-2025
21 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $655 · 2023: $976 · 2024: $320 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,569.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $944.69 | 2021-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $700.44 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $696.45 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $374.60 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $322.61 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $280.58 | 2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $224.52 | 2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $190.02 | 2021-2022 | |
| Abbvie INC. | $184.99 | 2025 | |
| Corium, LLC | $155.15 | 2025 | Azstarys |
| Lundbeck LLC | $72.77 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $70.96 | 2021 | |
| Janssen Pharmaceuticals, INC | $61.34 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $59.54 | 2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $42.70 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37.07 | 2025 | Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.57 | 2025 | Caplyta |
| Almatica Pharma LLC | $32.26 | 2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $27.68 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $23.86 | 2025 | Qelbree |
| Sumitomo Pharma America, INC. | $17.21 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Oldham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.